KNKhanh Nguyen

Khanh Nguyen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Khanh Nguyen has a total of 111 co-authors. Here are the top co-authors by number of shared publications:

  • Amy Moskop

    10Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI

    5 shared publications
  • Christine L. Phillips

    Department of Pediatrics, Cancer and Blood Disease Institute, Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH

    5 shared publications
  • Julie-An Talano

    10Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI

    5 shared publications
  • Kevin J. Curran

    22Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY

    5 shared publications
  • Michelle L. Hermiston

    Department of Pediatrics University of California San Francisco San Francisco California USA

    5 shared publications
  • Prakash Satwani

    18Department of Pediatrics, Columbia University Medical Center, New York, NY

    5 shared publications

Latest Publications

  • Peripheral blasts at apheresis as a risk factor for survival after tisagenlecleucel in children and young adults

    by Kaylyn Utley Lyons, Kristen R. Miller, Arpita Deb, Andrew Nicklawsky, Christina Baggott, Khanh Nguyen, Snehit Prabhu, Holly Pacenta, Christine L. Phillips, Jenna Rossoff, et al.

    Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood malignant neoplasm. Relapsed or refractory (R/R) B-ALL carries a dismal prognosis. CD19-specific chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment, yet relapse rates among responders remain high, with 40% to 50% experiencing relapse after therapy. This underscores the need for improved strategies to predict and prevent relapses after CAR T-cell therapy. This study reports the impact of peripheral blasts at the time of apheresis on outcomes in pediatric and young adult patients with R/R B-ALL treated with CD19-specific CAR T-cell therapy. A multi-institutional cohort of 162 patients from the Pediatric Real-World CAR Consortium was retrospectively analyzed. Key outcomes, such as day 28 response, event-free survival (EFS), and overall survival (OS), were evaluated based on the presence vs absence of peripheral blasts at apheresis. Although response at day 28 was comparable among peripheral blast groups in this cohort, the presence of peripheral blasts at apheresis was associated with inferior EFS (27% vs 55% at 12 months) and OS (55% vs 78% at 12 months). However, this association was confounded by disease burden at the time of infusion. In multivariable analysis, higher blast percentage at apheresis was not associated with an increased hazard of death (hazard ratio, 1.11; 95% confidence interval, 0.93-1.33; P = .25). These findings suggest that the association between peripheral blasts at apheresis and inferior survival is largely influenced by disease burden at infusion.

  • Open Access

    Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucel

    by Lauren E. Appell, Christina Baggott, Khanh Nguyen, Snehit Prabhu, Holly Pacenta, Samuel John, Vanessa A. Fabrizio, Christine L. Phillips, Jenna Rossoff, Julie-An Talano, et al.

  • Open Access

    Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel

    by Swati Naik, Subodh Selukar, Aimee C. Talleur, Samira Deshpande, Gabriela Llaurador Caraballo, Vanessa A. Fabrizio, Rayne H. Rouce, Xiaopei L. Zeng, Anant Vatsayan, Jenna Rossoff, et al.

    Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymphoblastic leukemia treated with tisagenlecleucel. We conducted a multi-institutional study involving 326 CAYAs, with 144 evaluable in an initial training cohort and 141 evaluable in a validation cohort, through the Pediatric Real-World CAR Consortium to characterize the incidence and outcomes of prolonged severe neutropenia (PSN) and to develop a predictive risk score for PSN, tailored for use in this population. The incidence of PSN, defined as an absolute neutrophil count of <0.5 x 103 cells per μL for ≥30 days, was 15.3% in the initial training cohort and 21% in the validation cohort. Development of PSN was associated with inferior overall survival (P < .001), relapse-free survival (P = .01), higher nonrelapse mortality (P = .003), and a greater risk of infections within 30 days (P = .03). Multivariable penalized regression analysis identified key risk factors for PSN, which included preinfusion C-reactive protein and bone marrow disease burden, and postinfusion peak ferritin and occurrence of severe cytokine release syndrome, which were used to create the CytoRisk score. In the validation cohort, the CytoRisk score discriminated between patients with and without PSN (area under the curve, 0.90; specificity, 93%; sensitivity, 71%; positive predictive value, 74%; and negative predictive value, 92%). The CytoRisk score may be used to a priori identify patients at highest risk of PSN and overall worse outcomes.


  • Open Access

    Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy

    by Hannah Lust, Liora M. Schultz, Soyang Kwon, Gregory W. Roloff, Ibrahim Aldoss, Christina Baggott, Samuel John, Jenna E. Rossoff, Kevin O. McNerney, Vanessa A. Fabrizio, et al.

    Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinct analysis of YAs receiving commercial CD19 CAR T has not been reported. Using retrospective data from the Pediatric Real-World CAR T Consortium and the Real-World Outcomes of CAR T in Adult ALL collaboration, we describe the efficacy and safety of tisa-cel and brexu-cel in 70 YAs (18-26 years; tisa-cel, n = 50; brexu-cel, n = 20). Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) were observed more frequently for brexu-cel vs tisa-cel (CRS, 85% vs 56%; ICANS, 40% vs 18%). Complete response rates were similar between products at 80% for brexu-cel and 88% for tisa-cel. Relapse-free survival (RFS) at 12 months was 46% for brexu-cel and 36% for tisa-cel. Durability of remission over 12 months was 61% for brexu-cel vs 41% for tisa-cel; 12-month overall survival (OS) for brexu-cel was 84% vs 68% for tisa-cel. In multivariate analysis, low disease burden was associated with improved OS, whereas inotuzumab before CAR T was associated with inferior outcomes. This study demonstrates comparable real-world efficacy among YAs receiving CD19 CAR T irrespective of CAR T construct; however, rates of toxicity seem higher with brexu-cel.


  • Open Access

    Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults

    by Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M. Hsieh, Kevin McNerney, Rayne H. Rouce, Rebecca A. Gardner, Sara Ghorashian, Nirali N. Shah, Shannon L. Maude

    Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon L. Adam J. Lamble, Liora M. Schultz, Khanh Nguyen, Emily M Hsieh, Kevin McNerney, Rayne H Rouce, Rebecca A Gardner, Sara Ghorashian, Nirali N Shah, Shannon L.


  • Open Access

    Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns

    by Valentin Barsan, Yimei Li, Snehit Prabhu, Christina Baggott, Khanh Nguyen, Holly Pacenta, Christine L. Phillips, Jenna Rossoff, Heather Stefanski, Julie-An Talano, et al.